青少年和年轻成人霍奇金淋巴瘤：通过协作科学和多学科护理提高标准。
Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.
机构信息
Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University, Medical Center, New York, New York.
Jacobs School of Medicine and Biomedical Sciences, Roswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo, New York.
出版信息
Pediatr Blood Cancer. 2018 Jul;65(7):e27033. doi: 10.1002/pbc.27033. Epub 2018 Mar 30.
Abstract
Hodgkin lymphoma (HL) is one of the most common cancers in the adolescent and young adult (AYA) population (15-39 years). Despite continued improvements in HL outcomes, AYAs have not exhibited survival gains to the same extent as other age groups. At present, details about tumor biology, optimal therapeutic approaches, supportive care needs, and long-term toxicities in AYAs with HL remain understudied. Herein, we summarize the current state of the AYA population with HL, specifically focusing on how collaborations across the pediatric and medical oncology divide, coupled with multidisciplinary patient care, can further optimize outcomes for this group of patients.
摘要
霍奇金淋巴瘤（HL）是青少年和年轻成人（AYA）人群中最常见的癌症之一（15-39 岁）。尽管 HL 的治疗效果持续改善，但 AYA 患者的生存率并未像其他年龄组那样得到同等程度的提高。目前，关于 AYA 患者的 HL 肿瘤生物学、最佳治疗方法、支持性护理需求和长期毒性等方面的详细信息仍研究不足。本文总结了 HL 中 AYA 人群的现状，特别关注儿科肿瘤学和医学肿瘤学之间的合作，以及多学科患者护理如何进一步优化这组患者的治疗效果。
相似文献
1
Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.
Pediatr Blood Cancer. 2018 Jul;65(7):e27033. doi: 10.1002/pbc.27033. Epub 2018 Mar 30.
2
Classic Hodgkin Lymphoma in Adolescents and Young Adults.
J Clin Oncol. 2024 Feb 20;42(6):653-664. doi: 10.1200/JCO.23.01799. Epub 2023 Nov 20.
3
Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma.
Curr Treat Options Oncol. 2021 Jun 7;22(7):64. doi: 10.1007/s11864-021-00861-0.
4
AYA Considerations for Aggressive Lymphomas.
Curr Hematol Malig Rep. 2021 Feb;16(1):61-71. doi: 10.1007/s11899-021-00607-7. Epub 2021 Mar 16.
5
The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?
Blood. 2018 Jul 26;132(4):376-384. doi: 10.1182/blood-2018-01-778548. Epub 2018 Jun 12.
6
Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26681. Epub 2017 Jun 14.
7
Current considerations in AYA Hodgkin lymphoma.
Br J Haematol. 2019 Jan;184(1):72-81. doi: 10.1111/bjh.15640. Epub 2018 Nov 20.
8
An Age Stratified Analysis of the Access to Care Continuum Across Three Tumor Groups: Are There Delays for AYA?
J Adolesc Young Adult Oncol. 2019 Aug;8(4):402-409. doi: 10.1089/jayao.2018.0126. Epub 2019 Mar 26.
9
Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.
J Adolesc Young Adult Oncol. 2019 Dec;8(6):684-696. doi: 10.1089/jayao.2019.0016. Epub 2019 Aug 14.
10
Hodgkin lymphoma in children and adolescents: improving the therapeutic index.
Hematology Am Soc Hematol Educ Program. 2015;2015:514-21. doi: 10.1182/asheducation-2015.1.514.
引用本文的文献
1
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.
Bone Marrow Transplant. 2025 Sep 9. doi: 10.1038/s41409-025-02701-3.
2
Defining Practice Capacity for Cancer Care Delivery to Adolescents and Young Adults in the Community Setting: 2022 Landscape Assessment Results.
J Adolesc Young Adult Oncol. 2024 Jun;13(3):557-563. doi: 10.1089/jayao.2023.0177. Epub 2024 Feb 23.
3
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL.
JCO Oncol Pract. 2024 Apr;20(4):491-502. doi: 10.1200/OP.23.00328. Epub 2024 Jan 22.
4
Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma.
EJHaem. 2023 Sep 7;4(4):921-926. doi: 10.1002/jha2.787. eCollection 2023 Nov.
5
Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource-limited country: An observational study.
Cancer Rep (Hoboken). 2023 Aug;6(8):e1839. doi: 10.1002/cnr2.1839. Epub 2023 May 31.
6
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.
Bone Marrow Transplant. 2022 Aug;57(8):1217-1239. doi: 10.1038/s41409-022-01691-w. Epub 2022 May 19.
7
Effects of Continuous Care Combined with Evidence-Based Nursing on Mental Status and Quality of Life and Self-Care Ability in Patients with Liver from Breast Cancer: A Single-Center Randomized Controlled Study.
Comput Math Methods Med. 2022 Apr 28;2022:3637792. doi: 10.1155/2022/3637792. eCollection 2022.
8
Advances in Hodgkin Lymphoma: Including the Patient's Voice.
Front Oncol. 2022 Feb 25;12:855725. doi: 10.3389/fonc.2022.855725. eCollection 2022.
9
Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.
Lancet Haematol. 2022 Jan;9(1):e49-e57. doi: 10.1016/S2352-3026(21)00349-5.
10
A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.
Blood. 2022 Feb 10;139(6):889-893. doi: 10.1182/blood.2021011941.
本文引用的文献
1
Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.
Blood Adv. 2017 Oct 10;1(22):1945-1958. doi: 10.1182/bloodadvances.2017008748.
2
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2018 Jan;16(1):66-97. doi: 10.6004/jnccn.2018.0001.
3
Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives.
Adolesc Health Med Ther. 2017 Nov 29;8:137-148. doi: 10.2147/AHMT.S112757. eCollection 2017.
4
Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review.
Leuk Lymphoma. 2018 Aug;59(8):1976-1980. doi: 10.1080/10428194.2017.1406086. Epub 2017 Dec 7.
5
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10.
6
Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Cancer. 2018 Feb 15;124(4):816-825. doi: 10.1002/cncr.31114. Epub 2017 Nov 10.
7
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Lancet. 2017 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.
8
Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx058.
9
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Cancer. 2018 Jan 1;124(1):136-144. doi: 10.1002/cncr.30979. Epub 2017 Sep 13.
10
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9.
Zotero 插件